Lipid polymeric nanoparticles modified with tight junction-modulating peptides promote afatinib delivery across a blood –brain barrier model
ConclusionTJ-modulating peptide-modified LPN could be a prospective platform for the delivery of chemotherapeutics across the BBB to the brain for the potential treatment of the BM of NSCLC.
Source: Cancer Nanotechnology - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Brain | Brain Cancers | Cancer | Cancer & Oncology | Lung Cancer | Nanotechnology | Neurology | Non-Small Cell Lung Cancer | Study